Childhood cancer immunotherapy trial pulled before it started

NCT ID NCT04500548

Terminated Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study was designed to test two immunotherapy drugs, nivolumab and ipilimumab, in children and young adults with cancers that returned or didn't respond to treatment and had many genetic mutations. The goal was to see if the drug combination was safe and could shrink tumors. However, the trial was withdrawn before enrolling any participants, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab and ipilimumab (immunotherapy drugs)

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer central nervous system cancer Colorectal Neoplasms, Hereditary Nonpolyposis hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm lymphoma Lynch syndrome mismatch repair cancer syndrome mismatch repair cancer syndrome 1 neuroblastoma primary brain neoplasm refractory malignant neoplasm xeroderma pigmentosum

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY SYNDROME HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM LYNCH SYNDROME RECURRENT LYMPHOMA RECURRENT MALIGNANT SOLID NEOPLASM RECURRENT NEUROBLASTOMA RECURRENT PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM REFRACTORY LYMPHOMA REFRACTORY MALIGNANT SOLID NEOPLASM REFRACTORY NEUROBLASTOMA REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM XERODERMA PIGMENTOSUM

Contacts and locations

Locations

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

Houston, Texas, 77030, United States
British Columbia Children's Hospital

Vancouver, British Columbia, V6H 3V4, Canada
Children's Hospital Colorado

Aurora, Colorado, 80045, United States
Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States
Hospital for Sick Children

Toronto, Ontario, M5G 1X8, Canada
Lucile Packard Children's Hospital Stanford University

Palo Alto, California, 94304, United States
Seattle Children's Hospital

Seattle, Washington, 98105, United States
University of Wisconsin Carbone Cancer Center - University Hospital

Madison, Wisconsin, 53792, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.